Markets

Relief for Nektar after AADPAC Voting - Analyst Blog

A generic image of a person with a pen and a calculator
Credit: Shutterstock photo

Nektar Therapeutics ( NKTR ) announced that most of the members of the FDA's Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) have recommended that no cardiovascular outcomes study is required for the peripherally-acting mu-opioid receptor antagonist (PAMORA) class of drugs, which includes Movantik (naloxegol oxalate).

Movantik is being developed for the treatment of opioid-induced constipation (OIC) for patients suffering from chronic non-cancer pain. The committee however suggested that post-approval cardiovascular safety data collection for this class of candidates will continue.

The favorable voting comes as a huge relief for Nektar. Additional cardiovascular outcomes studies would have significantly spiked the company's research and development expenses. We note that Nektar's stock trading was halted yesterday before the advisory committee meeting. We expect the news to positively impact Nektar's shares.

Nektar has a worldwide licence agreement with AstraZeneca ( AZN ) for Movantik. Movantik is under review in the U.S. for the chronic non-cancer pain indication. A final decision from the FDA on the approval of Movantik is expected by Sep 16, 2014. We note that although the FDA is not bound to follow the advisory committee's opinion, but it generally does so. Movantik is also under review in the EU and Canada for the same indication.

Nektar also has NKTR-181 in its portfolio being developed for the treatment of chronic pain. The company is in discussion with the FDA regarding the design of a phase III study on NKTR-181 in chronic pain patients.

Nektar has progressed well with its pipeline in the last few quarters and is awaiting several pipeline related events in the coming quarters.

Nektar currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Gilead Sciences Inc. ( GILD ) and Ariad Pharmaceuticals Inc. ( ARIA ). While Gilead carries a Zacks Rank #1 (Strong Buy), Ariad holds a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ASTRAZENECA PLC (AZN): Free Stock Analysis Report

GILEAD SCIENCES (GILD): Free Stock Analysis Report

ARIAD PHARMA (ARIA): Free Stock Analysis Report

NEKTAR THERAP (NKTR): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

GILD AZN NKTR

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More